Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has allowed Vaccinex to begin VX15/2503 Phase 1 trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics in cancer patients with advanced solid tumors.
Subscribe to our email newsletter
VX15/2503 is a humanized antibody that blocks the activity of semaphorin 4D (SEMA4D).
Vaccinex plans to initiate a second trial of VX15/2503 for MS later this year.
Vaccinex president and CEO Maurice Zauderer said that SEMA4D is an exciting therapeutic target with remarkable biological properties relevant to several disease processes.
As reflected in its name, semaphorin, the molecule guides the activation and movement of different cell types in different ways," Zauderer said.
"The VX15/2503 antibody has the potential to be a radical new approach to treatment of MS, acting both as an anti-inflammatory to protect against disease progression but also promoting healing of damaged tissue."
Vaccinex is a biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies and vaccines to treat serious diseases with unmet needs.